Mr David Sorric, PHARMD in Blue Diamond, NV - Pharmacist

Mr David Sorric, PHARMD is a Pharmacist based in Blue Diamond, Nevada. Mr David Sorric is licensed to practice in Nevada (license number 14572) and his current practice location is 8 Lassen St, Box 123, Blue Diamond, Nevada. He can be reached at his office (for appointments etc.) via phone at (702) 249-8359.

NPI number for Mr David Sorric is 1144505868 and his current mailing address is 1524 Pinto Ln, Las Vegas, Nevada. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1144505868.

Contact Information

	Mr David Sorric, PHARMD
	8 Lassen St, Box 123, Blue Diamond, NV 89004-0123
	(702) 249-8359
	Not Available

Healthcare Provider's Profile

Full Name	Mr David Sorric
Gender	Male
Speciality	Pharmacist
Location	8 Lassen St, Blue Diamond, Nevada
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1144505868
Provider Enumeration Date: 10/13/2011
Last Update Date: 02/19/2013

Medical Identifiers

Medical identifiers for Mr David Sorric such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144505868	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	14572 (Nevada)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr David Sorric is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr David Sorric, PHARMD 1524 Pinto Ln, Las Vegas, NV 89106-4195 Ph: (702) 249-8359	Mr David Sorric, PHARMD 8 Lassen St, Box 123, Blue Diamond, NV 89004-0123 Ph: (702) 249-8359

News Archive

MMR booster does not result in worse JIA disease activity in children

Among children with juvenile idiopathic arthritis who had undergone primary immunization, the use of a measles-mumps-rubella booster compared with no booster did not result in worse JIA disease activity, according to a study in the June 19 issue of JAMA.

AstraZeneca CEO to take part in panel discussion on Ethical Practices in the Pharmaceutical Sector

David Brennan, CEO of AstraZeneca, will take part in the plenary session panel discussion on "Ethical Practices in the Pharmaceutical Sector" at the EuroMeeting 2012 in Copenhagen on Monday 26 March.

Roundup: Ga. AIDS Drug Assistance waiting list at zero; Mass. signs up for health law's disabled adults program

The state has eliminated a waiting list for a program that provides lifesaving medications to thousands of low-income, uninsured Georgians with HIV/AIDS more than two years after the list was first started. Established in July 2010, the wait list for Georgia's AIDS Drug Assistance Program rapidly ballooned to more than 1,600 - at one time becoming the largest in the country. A spike in the need for the program was largely fueled by the economic downturn as people lost their jobs and health insurance.

California's community hospitals launch public education and media campaign on H1N1

As preparations for the H1N1 flu season kick into high gear, California's community hospitals have launched a statewide public education and media campaign.

Research assesses the prevalence of overscreening for cancers among older adults

Older Americans may be receiving cancer screenings not recommended by the U.S. Preventive Services Task Force, according to Penn State College of Medicine researchers.

Mr David Sorric, PHARMD - Pharmacist in Blue Diamond, NV